Cartesian Therapeutics, Inc.
RNAC
Pozycja w akcjach
#18194
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Cena akcji
$6.44
Ostatnia synchronizacja: 2026-10-21
Kapitalizacja rynkowa
$194.84M
Zmiana (1 dzień)
0.70%
Zmiana (1 rok)
865.08%
Kraj
US
Handel Cartesian Therapeutics, Inc. (RNAC)
Kategoria
Healthcare
Historia ceny akcji dla Cartesian Therapeutics, Inc. (RNAC)
Najwyższa cena zamknięcia: $0.79 dnia 2023-12-01
Najniższa cena zamknięcia: $14.00 dnia 2016-06-01
Najniższa cena zamknięcia: $14.00 dnia 2016-06-01
Historia cen akcji firmy Cartesian Therapeutics, Inc. od 2016 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2023 | -33.64% |
| 2022 | -62.77% |
| 2021 | 0.01% |
| 2020 | 73.71% |
| 2019 | -58.81% |
| 2018 | -55.20% |
| 2017 | -51.08% |
| 2016 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.10 | -4.29% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
